Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Helo system offers minimally invasive solution for chronic venous thromboembolism (opens in a new tab)

news-medical.net · 2026-10-27

Short answerEvidenceSource

Short answer

Not supported

Not supported.

3 claims go further than the study. 3 other points were not covered by the paper.

  • 3 overstated
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Not supported

Three of six claims overstate the study. Three claims the study doesn't address.

  • 3 overstated
  • 3 not covered
Open claim evidence
3
Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedThe Hēlo Thrombectomy System, a medical device that quickly and efficiently removes blood clots in the lung for patients with chronic venous thromboembolism, was recently cleared by the U.S. Food and Drug Administration.View evidenceHide evidence

As statedquickly and efficiently

Why this verdict

The abstract profile supports that ENGULF studied the Hēlo PE thrombectomy catheter in intermediate-risk acute pulmonary embolism and reported successful procedures, RV/LV ratio reduction, and no major adverse events through 30 days. However, the story’s lead goes beyond the abstract by stating FDA clearance, characterizing removal as “quickly and efficiently,” and describing the indicated patients as having chronic venous thromboembolism rather than the paper’s intermediate-risk acute PE population.

1

Study evidence

Procedural feasibility: all 25 enrolled patients underwent a successful thrombectomy procedure with the Hēlo PE catheter.

“A prospective, single-arm feasibility study evaluating the Hēlo PE catheter was performed in patients presenting with intermediate-risk PE.”
2

Study evidence

Pre- to post-procedure RV/LV ratio on CTA decreased (mean 1.53 ± 0.27 preprocedure to 1.15 ± 0.18 postprocedure).Mean reduction 0.38 in RV/LV (23.2 ± 12.81% decrease from baseline)

“Patients underwent preprocedural and postprocedural computed tomography angiography.”
Claim 2 of 6OverstatedThe Hēlo Thrombectomy System uses suction to draw the clot into its catheter and an agitator, allowing for targeted and efficient removal.View evidenceHide evidence

As statedtargeted and efficient

Why this verdict

The paper profile supports that the device is a catheter-based mechanical thrombectomy system with a flexible collapsible funnel and internal agitator, and that all procedures were reported successful in a small first-in-human cohort. The abstract profile does not specifically verify suction as described, and the claim that this allows “targeted and efficient” removal is stronger than the single-arm feasibility and surrogate-endpoint evidence can establish.

1

Study evidence

Procedural feasibility: all 25 enrolled patients underwent a successful thrombectomy procedure with the Hēlo PE catheter.

“A prospective, single-arm feasibility study evaluating the Hēlo PE catheter was performed in patients presenting with intermediate-risk PE.”
2

Study evidence

Pre- to post-procedure RV/LV ratio on CTA decreased (mean 1.53 ± 0.27 preprocedure to 1.15 ± 0.18 postprocedure).Mean reduction 0.38 in RV/LV (23.2 ± 12.81% decrease from baseline)

“Patients underwent preprocedural and postprocedural computed tomography angiography.”
Claim 3 of 6OverstatedThe company reported positive results in the ENGULF trial, described as a key clinical trial evaluating the Hēlo system for treatment of pulmonary embolism, and those results helped pave the way for FDA clearance.View evidenceHide evidence

As statedpositive results

Why this verdict

The profile supports that ENGULF was a clinical feasibility study of the Hēlo PE catheter for pulmonary embolism and reported favorable early safety/procedural and RV/LV-ratio results. But the claim that these results helped pave the way for FDA clearance is a regulatory-causal claim not established by the supplied abstract profile, which does not discuss FDA clearance.

1

Study evidence

Procedural feasibility: all 25 enrolled patients underwent a successful thrombectomy procedure with the Hēlo PE catheter.

“A prospective, single-arm feasibility study evaluating the Hēlo PE catheter was performed in patients presenting with intermediate-risk PE.”
2

Study evidence

Pre- to post-procedure RV/LV ratio on CTA decreased (mean 1.53 ± 0.27 preprocedure to 1.15 ± 0.18 postprocedure).Mean reduction 0.38 in RV/LV (23.2 ± 12.81% decrease from baseline)

“Patients underwent preprocedural and postprocedural computed tomography angiography.”
Claim 4 of 6Not coveredThe device originated from a collaboration at the University of Michigan and was developed at the Biomedical Manufacturing and Design Lab led by Albert Shih.View evidenceHide evidence

Why this verdict

The abstract-level paper profile does not address University of Michigan origins, the Biomedical Manufacturing and Design Lab, or Albert Shih’s role. This may be true from other sources, but it is not verifiable from the supplied abstract profile.

Claim 5 of 6Not coveredThe technology was originally designed for stroke intervention but evolved to remove lung clots, also known as pulmonary embolisms.View evidenceHide evidence

Why this verdict

The supplied abstract profile describes the Hēlo PE catheter as a novel PE thrombectomy catheter but does not discuss any prior stroke-intervention design history or evolution from stroke technology.

Claim 6 of 6Not coveredEndovascular Engineering, founded in 2020, is leading commercialization efforts and has raised $42 million in Series B financing and $80 million in Series C financing.View evidenceHide evidence

As stated$42 million in Series B financing and $80 million in Series C financing

Why this verdict

The abstract-level paper profile does not discuss Endovascular Engineering’s founding date, commercialization role, or Series B/Series C financing amounts.

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • ENGULF was a prospective, multicenter, single-arm first-in-human feasibility study of the Hēlo PE thrombectomy catheter in 25 patients at 8 centers.

    The story mentions ENGULF as a key clinical trial with positive results, but it does not convey the first-in-human feasibility design, small sample size, single-arm structure, or multicenter 25-patient scope.

    From Prospective single-arm feasibility study

  • The studied population was patients with intermediate-risk acute pulmonary embolism, not chronic venous thromboembolism as stated in the story summary/lead claim.

    The paper profile repeatedly identifies the study population as intermediate-risk acute PE. The story’s framing around chronic venous thromboembolism does not match the abstract-profile population.

    From Prospective single-arm feasibility study; Prospective single-arm feasibility study

  • Primary safety findings included no deaths, major bleeding meeting VARC-2 major life-threatening criteria, pulmonary injury, or vascular complications at 48 hours or 30 days.

    The story’s phrase “positive results” is too nonspecific to reflect the specific safety endpoints and limited 48-hour/30-day follow-up reported in the abstract profile.

    From Prospective single-arm feasibility study

  • The primary efficacy endpoint was a pre- to post-procedure CTA RV/LV ratio change, an imaging surrogate; mean RV/LV decreased from 1.53 ± 0.27 to 1.15 ± 0.18, a 23.2% mean relative reduction.

    The story does not identify the main efficacy measure as an imaging surrogate or report the RV/LV ratio results; it only broadly characterizes trial results as positive.

    From Prospective single-arm feasibility study

  • All 25 patients underwent successful thrombectomy with the Hēlo PE catheter, but two patients also received adjunctive catheter-directed embolectomy with an alternative device.

    The story highlights efficient removal and positive trial results but does not mention adjunctive alternative-device use, which matters for attributing outcomes to Hēlo alone.

    From Prospective single-arm feasibility study; Prospective single-arm feasibility study

  • Two patients required postprocedural transfusion for anemia, although these events did not meet VARC-2 criteria for major life-threatening bleeding.

    This safety nuance is not reflected in the story, which does not discuss adverse events beyond a broad positive-results framing.

    From Prospective single-arm feasibility study

  • Key limitations were single-arm nonrandomized design, no concurrent control group, small sample size, short follow-up to 30 days, surrogate imaging endpoint, and possible confounding from adjunctive alternative-device embolectomy in two patients.

    The only caveat the story mentions is a financial-interest disclosure. It does not acknowledge the interpretation-changing scientific limitations of the ENGULF evidence.

    From Prospective single-arm feasibility study; Prospective single-arm feasibility study

  • The abstract profile supports only early safety/feasibility and preliminary surrogate efficacy, not definitive clinical efficacy, speed, efficiency, long-term outcomes, or regulatory clearance causation.

    The story presents stronger device-performance and regulatory implications than the abstract-level evidence supports and does not preserve the paper’s feasibility-study framing.

    From Prospective single-arm feasibility study; Prospective single-arm feasibility study

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate the safety and feasibility of the novel Hēlo PE thrombectomy catheter for treatment of intermediate-risk acute pulmonary embolism in a first-in-human, multicenter setting.Prospective single-arm feasibility studyExpand

In plain English

Prospective, multicenter, single-arm first-in-human feasibility study (ENGULF) of the Hēlo PE thrombectomy catheter in 25 patients with intermediate-risk acute pulmonary embolism. Procedures were completed successfully in all enrolled patients. Pre- and postprocedural CT angiography measured RV/LV ratio as the prespecified efficacy metric; safety outcomes (all-cause mortality, major life-threatening bleeding, device-related serious adverse events, pulmonary or cardiac injury, clinical decompensation) were assessed at 48 hours and 30 days. Postprocedure RV/LV ratio decreased from 1.53 ± 0.27 to 1.15 ± 0.18 (mean relative reduction 23.2% ± 12.81%). No deaths, major bleeding, pulmonary injury, or vascular complications were reported at 48 hours or 30 days. Two patients required postprocedural transfusion for anemia but did not meet VARC-2 criteria for major life-threatening bleeding; two patients received adjunctive catheter-directed embolectomy with an alternative device. The authors conclude the device was feasible and safe in this first-in-human cohort.

Key findings

  • Procedural feasibility: all 25 enrolled patients underwent a successful thrombectomy procedure with the Hēlo PE catheter.
  • Prespecified efficacy surrogate (RV/LV ratio) improved after the procedure.Mean RV/LV reduced from 1.53 ± 0.27 to 1.15 ± 0.18; mean relative reduction 23.2% ± 12.81%.
“A prospective, single-arm feasibility study evaluating the Hēlo PE catheter was performed in patients presenting with intermediate-risk PE.”
What this piece can’t prove
  • Single-arm, nonrandomized first-in-human feasibility study without a concurrent control group.
  • Small sample size (25 patients) across 8 centers limits statistical precision.
  • Short follow-up reported in abstract (48 hours and 30 days) — longer-term outcomes not provided.
  • Two patients received adjunctive catheter-directed embolectomy with an alternative device, which may affect attribution of outcomes to the studied device.
  • Primary efficacy endpoint is an imaging surrogate (RV/LV ratio) rather than direct clinical outcomes in this abstract.
2human in vivoEstimate preliminary device efficacy via pre- vs post-procedure change in RV/LV ratio on computed tomography angiography (CTA).Prospective single-arm feasibility studyExpand

In plain English

Prospective, single-arm multicenter feasibility study (ENGULF) evaluated change in RV/LV ratio on pre- and post-procedure CTA as the prespecified primary efficacy endpoint after use of the Hēlo PE thrombectomy catheter in patients with intermediate-risk pulmonary embolism. Among 25 patients, mean RV/LV decreased from 1.53 ± 0.27 preprocedure to 1.15 ± 0.18 postprocedure, representing a 23.2 ± 12.81% mean reduction. All procedures were reported as successful; no adjunctive systemic thrombolysis was used (two patients received an alternative adjunctive catheter device).

Key findings

  • Pre- to post-procedure RV/LV ratio on CTA decreased (mean 1.53 ± 0.27 preprocedure to 1.15 ± 0.18 postprocedure).Mean reduction 0.38 in RV/LV (23.2 ± 12.81% decrease from baseline)
“Patients underwent preprocedural and postprocedural computed tomography angiography.”
What this piece can’t prove
  • Small sample size (25 patients) from a first-in-human feasibility study.
  • Single-arm design without a contemporaneous control group.
  • Abstract lacks details on timing and standardized protocol for postprocedural CTA and on blinding/repeatability of RV/LV measurements.
  • Two patients received adjunctive alternative-device embolectomy, potentially confounding the imaging endpoint in those cases.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

SelectedOpen access

A Safety and Feasibility Single-Arm Study of a Novel Catheter Thrombectomy Device for the Treatment of Pulmonary Embolism (ENGULF).

Journal of the Society for Cardiovascular Angiography & Interventions · 2024 · PubMed, Europe PMC

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Emergent mechanical thrombectomy for right atrial clot and massive pulmonary embolism using FlowTriever.

2020 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.